The Economic Times  Jul 22  Comment 
Company, which follows January-December as its fiscal year, said it's Board of Directors has declared an interim dividend of Rs 18 per equity share of Rs 10 each.
The Economic Times  Jul 21  Comment 
Insulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-selling list of drugs in the country.
Reuters  Jul 18  Comment 
BRUSSELS - French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim's consumer health unit by offering concessions.
Motley Fool  Jul 17  Comment 
As rivals Facebook and Snapchat continue to expand their video offerings, Twitter's latest live-streaming deal could help finally reignite the platform's long-dormant user growth.
Motley Fool  Jul 13  Comment 
Continuing concerns over Praluent weigh on Regeneron, but shareholders would be wise to look at the whole picture.
Motley Fool  Jul 12  Comment 
Amgen has won FDA approval for a new device that allows for monthly dosing of its cholesterol-busting drug Repatha. Is it a game-changing innovation in its fight against Regeneron Pharmaceuticals and Sanofi?
Motley Fool  Jul 9  Comment 
M&A rumors failed to spark investor interest following the company's decision to shutter research on key Duchenne drugs.
Reuters  Jul 8  Comment 
BRUSSELS - German drugmaker Boehringer Ingelheim has offered concessions in an attempt to win EU antitrust approval for its $20 billion asset swap with France's Sanofi , which would make it the...
Clusterstock  Jul 7  Comment 
Medivation is the drug industry's hottest takeover target, and it is doing everything it can to milk that.  The company has received at least two bids from Sanofi that Medivation has rejected, and earlier this week said it entered into...

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki